The Honda Question: What Happens When Someone Else Builds a Better Pill

Saw a story this week about a Chinese biotech team aiming to get a “smart” probiotic for type 2 diabetes onto US shelves within two years. Uses gut bacteria and GLP-1 pathways to help regulate blood sugar. Cheaper than Ozempic, apparently, and without the injections. My first thought wasn’t about the science. It was about what happens next, and whether “next” ever actually arrives.

Someone in the comments made a comparison I hadn’t considered: this could go the way of the Japanese auto industry in the 70s and 80s. Detroit kept making the same overpriced, undercooked cars while Japanese manufacturers quietly built something better and cheaper, and by the time anyone in Michigan looked up, the market had already moved. There’s a great line that came out of that era: Honda hired a thousand engineers, GM hired a thousand lawyers. I don’t know if that’s literally true, but it doesn’t need to be. It’s true in spirit, and that’s often enough.

Whether the same pattern plays out with pharma, I genuinely don’t know. American drug companies aren’t short on lawyers either, and the regulatory moat around the US healthcare system is deep and well-defended. My hunch, and it really is just a hunch, is that if this probiotic works as advertised, the FDA approval will take forever, someone will find a patent angle to block it, and eventually a US company will either buy the licence or reverse-engineer something close enough. Not because the system is efficient, but because the incentives to protect existing revenue are enormous. I’d love to be wrong about that.

What actually got under my skin was further down the thread, someone asking “what happened to people eating healthy and exercising?” as though that fixes it. Type 2 diabetes has a genetic component that no amount of kale addresses. My father-in-law eats well, walks every day, and still manages his blood sugar with medication because his body is doing something his lifestyle can’t override. I’ve watched him do everything right and still need the drugs. It’s not a morality play, it’s biology, and pretending otherwise is just a way of making sick people feel like they did something wrong.

There’s a real tension here I don’t think resolves neatly. I want cheaper, better treatments to reach people who need them, wherever they come from. I also think about the environmental and geopolitical cost of manufacturing at that scale, and about what it means when a handful of countries hold this much sway over what medicine looks like for the rest of us. Both things can be true: I want the treatment to exist, and I’m uneasy about how few hands control whether it does.

Australia’s not immune from any of this. We negotiate drug prices through the PBS in a way Americans mostly can’t imagine, and it’s one of the few times I feel genuinely proud of a piece of policy machinery. But even here, new treatments take years to clear listing processes, and people wait. If this probiotic actually works, and actually gets cheap, I hope it gets here faster than it’ll get through Washington. I’m not holding my breath. But I’ll take the win if it comes.